SAN DIEGO , Nov. 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced that Martin Brenner , DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran , Chief Financial Officer, will participate in the following investor conferences in November and December 2026 . Guggenheim Healthcare Innovation 2026 Conference When: November 9 - 11 Format: Fireside chat Date & Time: November 10, 2026 : 9:00 a.m. ET Location: Boston A livestream of the event can be accessed here . Jefferies Global Healthcare Conference When: November 16 - 19 Format: 1:1 Meetings Location: The Waldorf Hilton , London Piper Sandler 38th Annual Healthcare Conference Dates: December 1 - 3 Format: Fireside Chat Date & Time : December 1 , 9:30-9:55 a.m. ET Presenters: Martin Brenner , Felipe Duran Location: Lotte New York Palace , New York City A livestream of the event can be accessed from the events page of the iBio website. Dr. Brenner and Mr. Duran will be available for one-on-one meetings during each conference. A link to access each of the replays and presentations will be available on the Investor section of the iBio website for 90 days after the event. About iBio, Inc. iBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio's mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit www.ibioinc.com or follow us on LinkedIn. Investor Contact Matt Beckastr partners matthew.beck@astrpartners.com (917) 415-1750 Media Contact Jason Braco, Ph.D.Valence Communications jason@valencecomms.com Source: iBio, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.